<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01123538</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT-2006-004462-14</org_study_id>
    <secondary_id>2006-004462-14</secondary_id>
    <nct_id>NCT01123538</nct_id>
  </id_info>
  <brief_title>Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression Profile</brief_title>
  <acronym>ProGEP</acronym>
  <official_title>Progestagen Type in Postmenopausal Hormone Therapy and Blood Gene Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of North Norway</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare combined postmenopausal hormone therapy natural&#xD;
      progesterone to the one containing synthetic progestagen (i.e. chlormadinone acetate) at the&#xD;
      blood transcriptome level.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2008</start_date>
  <completion_date type="Anticipated">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole blood and white blood cells gene expression profiling after 3 months of HT treatment</measure>
    <time_frame>0 and 3 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life, proteome, plasma haemostatic variable measurements</measure>
    <time_frame>0,3,6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood and white blood cells gene expression profiling after 12 months of HT treatment</measure>
    <time_frame>0 and 12 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pharmacogenomics</condition>
  <condition>Systems Biology</condition>
  <arm_group>
    <arm_group_label>Natural progesterone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Combined menopausal treatment containing natural progesterone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlormadinone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Combined menopausal treatment containing chlormadinone acetate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year</description>
    <arm_group_label>Natural progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlormadinone acetate</intervention_name>
    <description>5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)</description>
    <arm_group_label>Chlormadinone acetate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women defined as:&#xD;
&#xD;
               -  45 years&lt; age &lt; 65 years&#xD;
&#xD;
               -  Amenorrhoeic for ≥ 1 year&#xD;
&#xD;
               -  Amenorrhoeic for &lt; 1 year either without any withdrawal vaginal bleeding for 3&#xD;
                  consecutive months in spite of a cyclic progestagen treatment and/or blood&#xD;
                  estradiol levels ≤ 20 pg/mL and blood FSH levels ≥ 40 UI/mL&#xD;
&#xD;
               -  Women with bilateral ovariectomy&#xD;
&#xD;
          -  Women suffering of at least 1 postmenopausal symptoms listed:&#xD;
&#xD;
               -  Hot flashes,&#xD;
&#xD;
               -  Memory and Concentration Problems,&#xD;
&#xD;
               -  Mood Swings,&#xD;
&#xD;
               -  Insomnia,&#xD;
&#xD;
               -  Urinary Incontinence,&#xD;
&#xD;
               -  Night sweating,&#xD;
&#xD;
               -  Join pains,&#xD;
&#xD;
               -  Asthenia.&#xD;
&#xD;
          -  No use of hormone therapy (HT)&#xD;
&#xD;
          -  Previous HT user:&#xD;
&#xD;
               -  HT use &lt; 3 months - stop for 6 months&#xD;
&#xD;
               -  HT use &lt;= 1 year - stop for &gt; 12 months&#xD;
&#xD;
          -  If previous use of soya derivatives in dietary supplements: washout period = 3 months&#xD;
&#xD;
          -  Signed informed consent, after having received both oral- and written- information&#xD;
             regarding the study goals, its risks and benefits and its constraints, including the&#xD;
             12 month follow-up. A delay should be respected between information and the signature&#xD;
             of the written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Past HT users who have used treatment for more than 1 year&#xD;
&#xD;
          -  Hysterectomized women&#xD;
&#xD;
          -  Women without health insurance (only in French centre)&#xD;
&#xD;
          -  History of cardio-vascular accident either arterial or venous&#xD;
&#xD;
          -  Untreated high blood pressure&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  History of cancer except basal-cell skin cancer and colon cancer&#xD;
&#xD;
          -  Severe history of familial breast cancer defined as at least 2 women first degree-&#xD;
             relatives with breast cancer diagnosis before 50 years&#xD;
&#xD;
          -  History of severe mastalgia&#xD;
&#xD;
          -  History of breast biopsy showing hyperplasia (with or without atypia)&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding&#xD;
&#xD;
          -  Diagnosed endometrial hyperplasia&#xD;
&#xD;
          -  Auto-immune disease (e.g. lupus)&#xD;
&#xD;
          -  Women with kidney transplant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eiliv Lund, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Community Medicine, Tromsø, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vanessa Dumeaux, PharmD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institute of community medicine, Tromsø, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecology center, Helse Nord</name>
      <address>
        <city>Bodø</city>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>May 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2010</study_first_posted>
  <last_update_submitted>November 2, 2011</last_update_submitted>
  <last_update_submitted_qc>November 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlormadinone Acetate</mesh_term>
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 21, 2016</submitted>
    <returned>January 17, 2017</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

